Clinical trial
LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
NCT00412997 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00412997 |
|---|---|
| Title | LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma |
| Official title | A Phase I Dose-escalation Study of LBH589 Administered Orally in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tumors, Cutaneous T-Cell Lymphoma |
| Intervention type | Drug |
| Interventions | LBH589 |
| Enrollment | 14 |
| Start date | Nov 1, 2006 |
| Primary completion | May 1, 2008 |
| First posted | Dec 19, 2006 |
| Last update posted | Nov 27, 2012 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: